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Most strikingly, the frequencies of resistance of Staphy-
ococcus aureus isolates to methicillin—–MRSA (84.1% vs
6.8%), Klebsiella pneumoniae to ceftazidime or cef-
riaxone (76.1% vs 27.1%), Acinetobacter baumannii to
mipenem (46.3% vs 29.2%), and Pseudomonas aeruginosa
o piperacilline (78.0% vs 20.2%) were also far higher in
he consortium’s ICUs, and the crude unadjusted excess
ortalities of device-related infections ranged from 23.6%
CVC-associated BSI) to 29.3% (VAP).
oi:10.1016/j.ijid.2010.02.1506
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In the United States, inﬂuenza causes an average of
6,000 deaths and 226,000 hospitalizations yearly. Rates of
nfection are highest among children. Rates of serious ill-
ess and death are highest among persons aged ‘‘65 years,
hildren aged <2 years, and persons of any age with medical
onditions that place them at higher risk for complications
rom inﬂuenza.
Annual inﬂuenza vaccination is the most effective
ethod for preventing inﬂuenza virus infection and its
omplications. Inﬂuenza viruses undergo frequent antigenic
hange (antigenic drift); patients need an annual vacci-
ation against the inﬂuenza viruses that are predicted on
he basis of viral surveillance data. Trivalent inactivated
nﬂuenza vaccine (TIV) can be used for any person aged
‘6 months, including those with high-risk conditions. Live,
ttenuated inﬂuenza vaccine (LAIV) may be used for healthy,
onpregnant persons aged 2—49 years.
The 2009 novel inﬂuenza A (H1N1) pandemic required
separate monovalent vaccine to be rapidly developed,
ith different vaccination recommendations from those for
easonal vaccines. The initially limited supply of vaccine
equired that early vaccination efforts target children and
oung adults, adults <65 years old with chronic medical
onditions, pregnant women, and healthcare personnel. By
anuary 2010, monovalent vaccine supply had increased suf-
ciently to allow all persons who wanted vaccination to
eceive it.
Vaccination coverage has remained low in most groups
or a variety of reasons, including the need for annual revac-
ination, the complexity of vaccination recommendations,
nd a lack of knowledge among patients and healthcare
roviders. In recent years, simpler age-based recommen-
ations have been added for persons 50-64 years old, and
hildren ages 6 months through 18 years, and in 2009, >85%
f the US population had an indication for annual vacci-
ation. As more manufacturers have entered the market,
easonal vaccine supply has met demand. A universal vac-
ine recommendation for all persons aged 6 months or older
s feasible and has been proposed as a way to increase vac-
ine coverage in all age groups.
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Current inﬂuenza vaccines are safe in all age and risk
roups and quite effective in healthy children and younger
dults. Lower effectiveness among seniors and persons
ith chronic medical conditions, and lower immunogenicity
requiring 2 doses) among previously unvaccinated infants
nd children highlight unmet challenges. More effective vac-
ines are needed that can be more rapidly produced and can
vercome challenges such as immunosenescence, annual
evaccination, and lower protection against drifted viruses.
deally, better vaccines would stimulate longer-lasting cross-
eactive immunity against multiple strains.
Vaccines must be effective in protecting the very young,
he chronically ill, and the elderly, who bear the largest
urden of inﬂuenza illness. Also needed is a better under-
tanding of how to motivate people to seek annual inﬂuenza
accination.
oi:10.1016/j.ijid.2010.02.1507
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Among the limitations of seasonal inﬂuenza vaccines are
imited breadth of immunity, short duration of protection,
ower protection in older individuals and immunocompro-
ised patients, problems with needle inoculation such as
eedle phobia and medical waste disposal, and dependence
n the egg supply. Because antigenic drift (poor antigenic
atch between the vaccine and circulating strains) is asso-
iated with a fall in efﬁcacy, there is a need for vaccines
hat will induce an immune response to both identical and
elated strains. In an effort to produce broadened immunity,
ew adjuvanted vaccines with different oil components have
een formulated, and the concept of a universal inﬂuenza
accine continues to be explored. It is not clear whether
roducing a higher titer postvaccination will result in longer
uration of protection, as that requires speciﬁc evaluation
nvolving major practical difﬁculties. Improved technology
or inﬂuenza vaccines may result in vaccines intended for
peciﬁc population segments, such as younger children and
he elderly. A quadrivalent vaccine may be developed con-
aining the two A subtypes and the two B lineages, which
ould be most useful in children. To combat the issue of
mmunosenescence, a high-dose vaccine has recently been
pproved for use in older patients. Some studies suggest that
nvaccinated older individuals may be more ill but because
f their disability, underutilize the healthcare system; in
ontrast, vaccinated older individuals may be healthier
ecause they are in care, indicating bias in analyses. It may
e possible that these new vaccines will produce protec-
ion in the immunocompromised, but this will need to be
valuated speciﬁcally. To address problems associated with
eedle inoculation, new delivery systems and alternative
outes to intramuscular administration have been devel-
ped, such as a nasal vaccine approved in the United States
n 2007 and an intradermal vaccine approved recently in
urope. Cell culture production of inﬂuenza vaccines may
mprove vaccine efﬁcacy and would reduce the system’s
